RESEARCH TRIANGLE PARK and SAN FRANCISCO, August 18, 2022—Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, and Syapse®, a leading real-world evidence company, today announced a partnership to deploy proprietary real-world data intelligence and analytics that will help identify suitable patients for oncology clinical trials—ultimately speeding up the enrollment process.
Study sponsors are increasingly looking outside of traditional academic sites to source specific patient populations, but without the data to pinpoint patients’ locations, recruitment can be extremely challenging. Research indicates that roughly four in five of all clinical trials are subject to delays, most of which occur at the enrollment stage. Not only are these delays problematic for patients who are waiting to access potentially life-saving oncology treatments, but they also can cost sponsors upwards of $20 million per month in combined expenses and lost revenues.
“We are constantly exploring for faster, more efficient ways to bring new oncology treatments to patients who need them,” said Dr. Jonathan Cotliar, Chief Medical Officer, Science 37. “Recent research shows that patient enrollment is the number one challenge facing oncology research executives. By partnering with Syapse, we will have the ability to tap into advanced data-intelligence capabilities to make effective trial identification and recruitment a reality for patients and sponsors.”
To facilitate enrollment and reduce patient burden, oncology research executives have begun to rely more on agile (hybrid) and fully decentralized models.
“The quality of treatments that health systems can deliver to patients is directly linked to the quality of the clinical trials conducted, which is why working with Science 37 is such a critical opportunity,” said Ken Tarkoff, CEO of Syapse. “We are confident that by combining Science 37’s agile capabilities with Syapse’s ability to rapidly identify patients using real-world data, and the oncology clinical trial expertise of Syapse’s health system partners, this partnership will open the door to faster and more effective recruitment in oncology research.”
There are already over 3,700 active oncology clinical trials worldwide, with research and development spending this year projected to reach at least US$70 billion—accounting for around one-third of all drug R&D budgets in 2022. According to projections, by 2026, there could be more than 10,500 oncology clinical trials.
About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization. For more information, visit https://www.science37.com.
Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care. By marrying clinical expertise with smart technologies, we transform data into evidence—and then into experience—in collaboration with our network of partners, who are committed to improving patients’ lives through community health systems. Together, we connect comprehensive patient insights to our network, to empower our partners in driving real impact and improving access to high-quality care. For more information, visit https://www.syapse.com
Science 37 // Gilmartin